



Supplemental Figure S3. Sensitivity and synergy of the Ven+Ruxolitinib combination in AML cell lines.

A panel of eight human AML cell lines (CML, HL-60, Marimo, MOLM14, OCI-AML2, OCI-AML3, U-937, UT-7) were profiled in vitro for sensitivity across a 7x7 matrix of possible combined doses of venetoclox and ruxolitinib. Two non-AML leukemic cell lines (K562 and RCH-ACV) were also tested for comparison. Dose response curves are shown for venetoclox, with the effects of increasing doses of ruxolitinib in combination with venetoclox indicated by curve color. Data points

represent the mean of 4 replicates \pm SEM. To the right of each cell line's dose response curves is a plot showing a heatmap of excess over Bliss additivity synergy scores for all tested dose combinations, where red, white, and blue coloration denote synergy, additivity, and antagonism, respectively. Mean synergy scores across all tested doses are shown above each plot.